Beijing Sun-Novo Pharmaceutical Research Balance Sheet Health
Financial Health criteria checks 5/6
Beijing Sun-Novo Pharmaceutical Research has a total shareholder equity of CN¥1.1B and total debt of CN¥466.8M, which brings its debt-to-equity ratio to 41.3%. Its total assets and total liabilities are CN¥2.1B and CN¥948.7M respectively. Beijing Sun-Novo Pharmaceutical Research's EBIT is CN¥236.4M making its interest coverage ratio -0.5. It has cash and short-term investments of CN¥694.2M.
Key information
41.3%
Debt to equity ratio
CN¥466.83m
Debt
| Interest coverage ratio | -0.5x |
| Cash | CN¥694.23m |
| Equity | CN¥1.13b |
| Total liabilities | CN¥948.73m |
| Total assets | CN¥2.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688621's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥844.5M).
Long Term Liabilities: 688621's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥104.2M).
Debt to Equity History and Analysis
Debt Level: 688621 has more cash than its total debt.
Reducing Debt: 688621's debt to equity ratio has increased from 9.3% to 41.3% over the past 5 years.
Debt Coverage: 688621's debt is well covered by operating cash flow (37.3%).
Interest Coverage: 688621 earns more interest than it pays, so coverage of interest payments is not a concern.